Apolipoprotein A1/C3/A5 haplotypes and serum lipid levels by Yin, Rui-Xing et al.
RESEARCH Open Access
Apolipoprotein A1/C3/A5 haplotypes and serum
lipid levels
Rui-Xing Yin
1*, Yi-Yang Li
1,2 and Chao-Qiang Lai
3*
Abstract
Background: The association of single nucleotide polymorphisms (SNPs) in the apolipoprotein (Apo) A1/C3/A4/A5
gene cluster and serum lipid profiles is inconsistent. The present study was undertaken to detect the association
between the ApoA1/C3/A5 gene polymorphisms and their haplotypes with serum lipid levels in the general
Chinese population.
Methods: A total of 1030 unrelated subjects (492 males and 538 females) aged 15-89 were randomly selected
from our previous stratified randomized cluster samples. Genotyping of the ApoA1 -75 bp G>A, ApoC3 3238C>G,
ApoA5 -1131T>C, ApoA5 c.553G>T and ApoA5 c.457G>A was performed by polymerse chain reaction and
restriction fragment length polymorphism combined with gel electrophoresis, and then confirmed by direct
sequencing. Pair-wise linkage disequilibria and haplotype analysis among the five SNPs were estimated.
Results: The levels of high-density lipoprotein cholesterol (HDL-C) and ApoA1 were lower in males than in
femailes (P < 0.05 for each). The allelic and genotypic frequencies of the SNPs were no significant difference
between males and females except ApoC3 3238C>G. There were 11 haplotypes with a frequency >1% identified in
the cluster in our population. At the global level, the haplotypes comprised of all five SNPs were significantly
associated with all seven lipid traits. In particular, haplotype G-G-C-C-A (6%; in the order of ApoA5 c.553G>T,
ApoA5 c.457G>A, ApoA5 -1131T>C, ApoC3 3238C>G, and ApoA1 -75bp G>A) and G-A-T-C-G (4%) showed
consistent association with total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), ApoA1, ApoB, and the
ApoA1/ApoB ratio. In addition, carriers of haplotype G-G-T-C-G (26%) had increased serum concentration of HDL-C
and ApoA1, whereas carriers of G-G-C-G-G (15%) had high concentrations of TC, triglyceride (TG) and ApoB. We
also found that haplotypes with five SNPs explain much more serum lipid variation than any single SNP alone,
especially for TG (4.4% for haplotype vs. 2.4% for -1131T>C max based on R-square) and HDL-C (5.1% for haplotype
vs. 0.9% for c.553G>T based on R-square). Serum lipid parameters were also correlated with genotypes and several
environment factors.
Conclusions: Several common SNPs and their haplotypes in the ApoA1/C3/A5 gene cluster are closely associated
with modifications of serum lipid parameters in the general Chinese population.
Introduction
Dyslipidemia is a common metabolic disorder that may
result from abnormalities in the synthesis, processing
and catabolism of lipoprotein particles. Elevated plasma
total cholesterol (TC) [1], triglyceride (TG) [2], low-den-
sity lipoprotein cholesterol (LDL-C) [3], and
apolipoprotein (Apo) B [4], together with decreased
levels of ApoA1 [4] and high-density lipoprotein choles-
terol (HDL-C) [5] are associated with an increased risk
of coronary artery disease (CAD). A number of epide-
miological studies have shown that in addition to envir-
onmental factors, genetic mechanisms may play a role
in determining susceptibility to dyslipidemia [6]. The
heritability estimates of the interindividual variation in
plasma lipid phenotypes from both twin and family stu-
dies are in the range of 40-60% [7], suggesting a consid-
erable genetic contribution, and discovery of the genes
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ApoA1 is the predominant protein component of
HDL-C, and is involved in the activation of lecithin:
cholesterol acyltransferase, which mediate the reverse
cholesterol transport from peripheral tissues to the liver
[8]. ApoC3 is a major component of TG-rich lipopro-
teins (chylomicrons and very low density lipoprotein)
and a minor component of HDL. The mature 79-
amino-acid ApoC3 protein is synthesized predominantly
in the liver but also to a lesser extent in the intestine. In
vitro studies have indicated that ApoC3 is a noncompe-
titive inhibitor of lipoprotein lipase, thereby suggesting
an important role in the catabolism of TG-rich lipopro-
teins [9]. ApoA5 is a secreted protein present in human
serum and is associated with specific lipoprotein parti-
cles. It was detectable in very low-density lipoprotein,
HDL, and chylomicrons. Serum ApoA5 is very low com-
pared with other apolipoproteins [10]. Human ApoA1/
C3/A5 gene resides in the ApoA1/C3/A4/A5 gene clus-
ter, a short region on chromosome 11q23-q24 [11,12].
The ApoA1/C3/A4/A5 gene cluster has been identified
as a candidate region for hyperlipidemia in particular for
hypertriglyceridemia and atherosclerosis [12,13]. The
association between single nucleotide polymorphisms
(SNPs) in the ApoA1/C3/A4/A5 gene cluster and
plasma or serum lipid levels in humans has been evalu-
ated in a large number of studies [13-30]. However, pre-
vious findings on the association of the SNPs in this
gene cluster with the changes in plasma lipid levels are
inconsistent [31-38]. Many of previous studies for this
gene cluster come from studies of hyperlipidemic sub-
jects [14,17,18,25,26,29,33,38] and CAD patients
[13,19,21,23,34,36,37]. Studies of differences in the asso-
ciation between ApoA1/C3/A5 gene polymorphisms and
serum lipid levels in normolipidemic men and women
are extremely limited. Therefore, the aim of the present
study was to detect the polymorphisms of ApoA1 -75
bp G>A (rs1799837), ApoC3 3238C>G (rs5128), ApoA5
-1131T>C (rs662799), ApoA5 c.553G>T (rs2075291)
and ApoA5 c.457G>A (rs3135507) and the association
of their haplotypes and serum lipid levels in the general
Chinese population.
Materials and methods
Study populations
A total of 1030 unrelated subjects who reside in 16 vil-
lages in Napo County, Guangxi Zhuang Autonomous
Region, People’s Republic of China were randomly
selected from our previous stratified randomized cluster
samples [39]. The age of the subjects ranged from 15 to
89 years, with an average age of 43.30 ± 17.69 years.
There were 492 males and 538 females. All of the sub-
jects were rural agricultural workers. The subjects had
no evidence of diseases related to atherosclerosis, CAD
and diabetes. None of them had been treated with b-
adrenergic blocking agents and lipid-lowering drugs
such as statins or fibrates. The present study was
approved by the Ethics Committee of the First Affiliated
Hospital, Guangxi Medical University. Informed consent
was obtained from all subjects after they received a full
explanation of the study.
Epidemiological survey
The survey was carried out using internationally stan-
dardized methods. Information on demographics, socio-
economic status, and lifestyle factors was collected with
standardized questionnaires. The alcohol information
included questions about the number of liangs (about
50 g) of rice wine, corn wine, rum, beer, or liquor con-
sumed during the preceding 12 months. Alcohol con-
sumption was categorized into groups of grams of
alcohol per day: < 25 and ≥ 25. Smoking status was
categorized into groups of cigarettes per day: < 20 and ≥
20. At the physical examination, several parameters,
such as height, weight, and waist circumference were
measured. Sitting blood pressure was measured three
times with the use of a mercury sphygmomanometer
after the subjects had a 5-minute rest, and the average
of the three measurements was used for the level of
blood pressure. Systolic blood pressure was determined
by the first Korotkoff sound, and diastolic blood pres-
sure by the fifth Korotkoff sound. Body weight, to the
nearest 50 grams, was measured using a portable bal-
ance scale. Subjects were weighed without shoes and in
a minimum of clothing. Height was measured, to the
nearest 0.5 cm, using a portable steel measuring device.
From these two measurements body mass index (BMI,
kg/m
2) was calculated.
Biochemical analysis
A venous blood sample of 8 mL was obtained from all
subjects after at least 12 hours of fasting. A part of the
sample (3 mL) was collected into glass tubes and used
to determine serum lipid levels. Another part of the
sample (5 mL) was transferred to tubes with anticoagu-
late solution (4.80 g/L citric acid, 14.70 g/L glucose, and
13.20 g/L tri-sodium citrate) and used to extract deoxyr-
ibonucleic acid (DNA). The levels of serum TC, TG,
HDL-C, and LDL-C in samples were determined by
enzymatic methods with commercially available kits
(RANDOX Laboratories Ltd., Ardmore, Diamond Road,
Crumlin Co. Antrim, United Kingdom, BT29 4QY; Daii-
chi Pure Chemicals Co., Ltd., Tokyo, Japan). Serum
ApoA1 and ApoB levels were detected by the immuno-
turbidimetric immunoassay using a commercial kit
(RANDOX Laboratories Ltd.). All determinations were
performed with an autoanalyzer (Type 7170A; Hitachi
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Center of the First Affiliated Hospital, Guangxi Medical
University [39].
DNA preparation and genotyping
Total genomic DNA was isolated from peripheral blood
leukocytes using the phenol-chloroform method [8,40].
The extracted DNA was stored at 4°C until analysis.
Genotyping of the five SNPs was performed by polymer-
ase chain reaction and restriction fragment length poly-
morphism (PCR-RFLP) [6,8,40]. The sequences of the
forward and backward primers used for ApoA1 -75 bp
G>A, ApoC3 3238C>G, and ApoA5 -1131T>C were 5’-
CACCCGGGAGACCTGCAAGC-3’ and 5’-TCTAAG-
CAGCCAGCTCTTGCA-3’,5 ’-CACTAGCCCAGAGA-
GAGGAGTGCC-3’ and 5’-CTGAGCCCAGCCGCA
CACTAA-3’,a n d5 ’-GATTGATTCAAGATGCATT-
TAGGAC-3’ and 5’-CCCCAGGAACTGGAGCGAAA
TT-3’ (Sangon, Shanghai, People’sR e p u b l i co fC h i n a ) ;
respectively. Both ApoA5 c.553G>T and ApoA5
c.457G>A are naturally occurring restriction enzyme
sites in the exon 4 of ApoA5 gene. To analyze these two
polymorphic markers, exon 4 was amplified using pri-
mers 5’-TCGGCGTATGGGTGGAAGAG-3’ and 5’-
GGCAGCAACTGAAGCCCTACAC-3’. Each reaction
system of a total volume of 25 μL, comprised 100 ng (3
μL) of genomic DNA; 0.8 μL of each primer (20 pmo1);
4 μL of 10 × buffer solution; 3 μLd N T P ;a n d0 . 4μL( 1
U) Taq polymerase. For the amplification, initial dena-
turation at 95°C for 5 min was followed by 30 cycles of
denaturation at 95°C for 15 s, annealing at 61°C for 1
min, and extension at 72°C for 1 min, with final exten-
sion at 72°C for 7 min. Each restriction enzyme reaction
was performed with 15 μL of amplified DNA; 2 μLo f
10 × buffer solution; and restriction ezyme (0.15 μLo r
1.5 U MspI for ApoA1 -75bp G>A, 0.2 U SstIf o r
A p o C 33 2 3 8 C > G ,3UTru1Io rMseI for ApoA5
-1131T>C, 4 U MspI for ApoA5 c.553G>T, and 4 U
NsbIo rFspI for ApoA5 c.457G>A) in a total volume of
20 μL digested at 37°C overnight. The digestive products
were separated by electrophoresis on sepharose gel. The
length of each digested DNA fragment was determined
by comparing migration of a sample with that of stan-
dard DNA marker. Stained with ethidium bromide, the
gel was visualized under ultraviolet light and photo-
graphed. Genotypes were scored by an experienced
reader blinded to epidemiological data and serum lipid
levels.
DNA sequencing
Twenty-eight samples (each genotype in two) detected
by the PCR-RFLP were also confirmed by direct sequen-
cing. The PCR products were purified by low melting
point gel electrophoresis and phenol extraction, and
then the DNA sequences were analyzed by using an ABI
Prism 3100 (Applied Biosyatems) in Shanghai Sangon
Biological Engineering Technology & Services Co., Ltd.,
People’s Republic of China.
Diagnostic criteria
The normal values of serum TC, TG, HDL-C, LDL-C,
ApoA1, ApoB levels and the ratio of ApoA1 to ApoB in
our Clinical Science Experiment Center were 3.10-5.17,
0.56-1.70, 0.91-1.81, 1.70-3.20 mmol/L, 1.00-1.76, 0.63-
1.14 g/L, and 1.00-2.50; respectively [39]. The indivi-
duals with TC>5.17 mmol/L and/or TG>1.70 mmol/L
were defined as hyperlipidemic [39]. Hypertension was
diagnosed according to the criteria of 1999 World
Health Organization-International Society of Hyperten-
sion Guidelines for the management of hypertension
[41]. The diagnostic criteria of overweight and obesity
were according to the Cooperative Meta-analysis Group
of China Obesity Task Force. Normal weight, over-
weight and obesity were defined as a BMI < 24, 24-28,
and>28 kg/m
2; respectively [39-41].
Statistical analysis
Epidemiological data were recorded on a pre-designed
form and managed with Excel software. The statistical
analyses were done with the statistical software package
SPSS 13.0 (SPSS Inc., Chicago, Illinois) or SAS 9.1 (SAS
Institute, Inc., Cary, North Carolina, USA). Quantitative
variables were expressed as mean ± standard deviation
(serum TG levels were presented as medians and inter-
quartile ranges). Qualitative variables were expressed as
percentages. Allele frequency was determined via direct
counting, and the standard goodness-of-fit test was used
to test the Hardy-Weinberg equilibrium. Difference in
genotype distribution between the groups was obtained
using the chi-square test. The difference in general char-
acteristics between males and females was tested by the
Student’su n p a i r e dt-test. The association of genotypes
and serum lipid parameters was tested by analysis of
covariance (ANCOVA). Age, BMI, blood pressure, alco-
hol consumption, and cigarette smoking were adjusted
for the statistical analysis. Pair-wise linkage disequilibria
(LD) among the five SNPs were estimated as correlation
coefficients using the HelixTree program (GOLDEN
Helix, Bozeman, MN, USA). For haplotype analysis, we
estimated haplotype frequencies using the expectation-
maximization algorithm, and determine the association
between haplotypes and lipid phenotypes using trend
regression analysis with the option of composite haplo-
type estimation implemented in HelixTree. P values
were further adjusted for multiple tests by a permuta-
tion test. The permutation test was conducted by chan-
ging the orders of dependant variable randomly against
the genotypes (under the null hypothesis - no
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Then haplotype trend regression was conducted based
o nt h es a m em o d e la n daP value was recorded. This
process was repeated 1000 times. The P values of 1000
permutations were sorted in a descending manner. If
the observed P value is less than or equal to the 950
th P
value, the association was considered statistically signifi-
cant. In order to evaluate the association of serum lipid
levels (TC ≤ 5.17 mmol/L = 1,>5.17 mmol/L = 2; TG ≤
1.70 mmol/L = 1,>1.70 mmol/L = 2; HDL-C < 0.91
mmol/L = 1, ≥ 0.91 mmol/L = 2; LDL-C ≤ 3.20 mmol/L
= 1,>3.20 mmol/L = 2; ApoA1 < 1.00 g/L = 1, ≥ 1.00 g/
L = 2; ApoB ≤ 1.14 g/L = 1,>1.14 g/L = 2; ApoA1/ApoB
<1 . 0 0=1 ,≥ 1.00 = 2) with genotypes (-75bp G>A: GG
= 1, GA = 2, AA = 3; 3238C>G: CC = 1, CG = 2, GG =
3; -1131T>C: TT = 1, TC = 2, CC = 3; c.553G>T: GG =
1, GT = 2; c.457G>A: GG = 1, GA/AA = 2) and several
environment factors, unconditional logistic regression
analysis with forward stepwise modeling was also per-
formed in the combined population of males and
females, males, and females; respectively. A P value of
less than 0.05 was considered statistically significant.
Results
Demographic and biochemical characteristics
The demographic and biochemical characteristics of the
participants according to sex are presented in Table 1.
The levels of body height, weight, systolic blood pres-
sure, diastolic blood pressure, pulse pressure; the preva-
lence of hypertension; and the percentages of subjects
who consumed alcohol or smoked cigarettes were higher
in males than in females (P < 0.05-0.001), whereas the
levels of BMI, HDL-C and ApoA1 were lower in males
than in females (P < 0.05 for all). There was no signifi-
cant difference in the levels of age, TC, TG, LDL-C,
ApoB, and the ratio of ApoA1 to ApoB (P >0 . 0 5f o r
all).
Results of electrophoresis and genotyping
After the genomic DNA of the samples was amplified
by PCR and imaged by agarose gel electrophoresis for
the ApoA1 -75 bp G>A, the PCR product of 259 bp
nucleotide sequences could be seen in the samples.
The GG, GA and AA genotypes are shown in Figure
1A. The PCR product of the ApoC3 3238C>G was 596
Table 1 Comparison of general characteristics and serum lipid levels of the participants according to sex
Parameter Male
(n = 492)
Female
(n = 538)
t (c
2) P
Age (years) 43.65 ± 18.35 42.98 ± 17.07 0.607 0.544
Height (cm) 156.69 ± 10.25 147.88 ± 6.36 16.725 0.000
Weight (kg) 53.45 ± 8.99 48.17 ± 7.51 10.260 0.000
Body mass index (kg/m
2) 21.64 ± 2.31 21.96 ± 2.76 -2.008 0.045
> 24 kg/m
2 [n (%)] 58 (11.79) 98 (18.22) 8.260 0.004
Systolic blood pressure (mmHg) 125.28 ± 17.14 120.55 ± 14.80 4.751 0.000
Diastolic blood pressure (mmHg) 77.61 ± 10.46 74.45 ± 9.24 5.147 0.000
Pulse pressure (mmHg) 47.70 ± 12.60 46.14 ± 11.35 2.090 0.037
Hypertensive prevalence [n (%)] 96(19.51) 52(9.67) 20.251 0.000
Cigarette smoking [n (%)]
Nonsmoker 200(40.6) 506(94.0)
< 20 cigarettes/day 138(28.1) 30(5.6)
≥ 20 cigarettes/day 154(31.3) 2(0.4) 348.801 0.000
Alcohol consumption [n (%)]
Nondrinker 186(37.8) 330(61.4)
< 25 g/day 192(39.0) 204(37.9)
≥ 25 g/day 114(23.2) 4(0.7) 141.320 0.000
Total cholesterol (mmol/L) 4.61 ± 1.01 4.69 ± 0.90 -1.344 0.179
Triglycerides (mmol/L) 1.00(0.58) 0.97(0.60) 0.206 0.837
HDL-C (mmol/L) 2.03 ± 0.49 2.09 ± 0.46 -2.027 0.043
LDL-C (mmol/L) 2.36 ± 0.74 2.44 ± 0.66 -1.834 0.067
Apolipoprotein (Apo) A1 (g/L) 1.43 ± 0.17 1.45 ± 0.13 -2.131 0.033
ApoB (g/L) 0.90 ± 0.22 0.92 ± 0.20 -1.528 0.127
ApoA1/ApoB 1.71 ± 0.58 1.66 ± 0.44 1.567 0.118
HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol. The value of triglyceride was presented as median (interquartile range).
The difference between the two sexes was determined by the Wilcoxon-Mann-Whitney test.
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types are shown in Figure 1B. The PCR product of the
ApoA5 -1131T>C was 188 bp nucleotide sequences.
The TT, TC and CC genotypes are shown in Figure
1C. The PCR product of the ApoA5 c.553G>T was
211 bp nucleotide sequences. The GG and GT geno-
t y p e sa r es h o w ni nF i g u r e1 D .T h eT Tg e n o t y p ew a s
not detected in our study population. The PCR pro-
duct of the ApoA5 c.457G>A was 211 bp nucleotide
sequences. The GG, GA and AA genotypes are shown
in Figure 1E.
Results of sequencing
The results were shown as GG, GA and AA genotypes
of the ApoA1 -75bp G>A; CC, CG and GG genotypes
of the ApoC3 3238C>G; TT, TC and CC genotypes of
the ApoA5 -1131T>C; GG and GT genotypes of the
ApoA5 c.553G>T; and GG, GA and AA genotypes of
the ApoA5 c.457G>A by PCR-RFLP, the genotypes were
also confirmed by sequencing (Figure 2); respectively.
We have deposited the raw data at Genbank’sG e n e
Expression Omnibus (GEO) database under accession
number GRP3220754.
Figure 1 Genotyping of the ApoA1/C3/A5 gene polymorphisms. (A) ApoA1 -75 bp G>A. Lane M, 50 bp marker ladder; lanes 1 and 2, the
PCR products of the samples (259 bp); lanes 3 and 4, GA genotype (254-, 176- and 78-bp); lanes 5 and 6, GG genotype (176- and 78-bp); and
lanes 7 and 8, AA genotype (254 bp). (B) ApoC3 3238C>G. Lane M, 100 bp marker ladder; lanes 1 and 2, the PCR products of the samples (596
bp); lanes 3 and 4, CC genotype (596 bp); lanes 5 and 6, CG genotype (596-, 371- and 225-bp); and lanes 7 and 8, GG genotype (371- and 225-
bp). (C) ApoA5 -1131T>C. Lanes 1 and 2, the PCR products of the samples (188 bp); lanes 3 and 4, TT genotype (165- and 23-bp); lanes 5 and 6,
TC genotype (188-, 165- and 23-bp); and Lanes 7 and 8, CC genotype (188 bp). The 23 bp fragment was invisible in the gel owing to its fast
migration speed. (D) ApoA5 c.553G>T. Lane M, 50 bp marker ladder; lanes 1 and 2, the PCR products of the samples (211 bp); lanes 3 and 4, GG
genotype (176- and 35-bp); lanes 5 and 6, GT genotype (211-, 176- and 35-bp). TT genotype was not detected in both sexes. The 35 bp
fragment was invisible in the gel owing to its fast migration speed. (E) ApoA5 c.457G>A. Lanes 1 and 2, the PCR products of the samples (211
bp); lanes 3 and 4, GG genotype (211 bp); lanes 5 and 6, GA genotype (211-, 133- and 78-bp); and lanes 7 and 8, AA genotype (133- and 78-bp).
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The genotypic frequencies of each of the five loci were
all in Hardy-Weinberg equilibrium (ApoA1 -75bp G>A:
c
2 = 3.492, P = 0.062; ApoC3 3238C>G: c
2 =0 . 1 0 8 ,P =
0.743; ApoA5 -1131T>C: c
2 = 1.524, P =0 . 2 1 7 ;A p o A 5
c.553G>T: c
2 =1 . 2 0 0 ,P = 0.273; ApoA5 c.457G>A: c
2
= 2.470, P = 0.116; respectively). For five SNPs, ApoA1
-75bp G>A was in LD with ApoC3 3238C>G (P <
0.001), ApoA5 -1131T>C (P < 0.04), ApoA5 c.553G>T
(P < 0.001), and ApoA5 c.457G>A (P <0 . 0 0 2 ) .A p o C 3
3238C>G was in LD with ApoA5 -1131T>C (P < 0.001).
ApoA5 -1131T>C was in LD with ApoA5 c.553G>T (P
< 0.001) and ApoA5 c.457G>A (P <0 . 0 0 1 ) .T h e r ew a s
no LD between ApoC3 3238C>G and ApoA5 c.553G>T
or ApoA5 c.457G>A; and between ApoA5 c.553G>T
and ApoA5 c.457G>A (P > 0.05 for all; Figure 3). The
frequency of ApoC3 3238C and 3238G alleles was 70.7%
and 29.3% in males, and 64.7% and 35.3% in females (P
< 0.01); respectively. The frequency of CC, CG and GG
genotypes was 51.2%, 39.0% and 9.8% in males, and
40.2%, 49.0% and 10.8% in females (P <0 . 0 1 ) ;r e s p e c -
tively. There was no difference in the genotypic and alle-
lic frequencies of the ApoA1 -75bp G>A, ApoA5
-1131T>C, ApoA5 c.553G>T, and ApoA5 c.457G>A
between the males and females (P > 0.05 for all; Table
2).
Figure 2 A part of the nucleotide sequences of the ApoA1/C3/A5 gene polymorphisms. (A) ApoA1 -75 bp G>A: (1) GG genotype, (2) GA
genotype, (3) AA genotype. (B) ApoC3 3238C>G: (1) CC genotype, (2) CG genotype, (3) GG genotype (C) ApoA5 -1131T>C: (1) TT genotype, (2)
TC genotype, (3) CC genotype; (D) ApoA5 c.553G>T: (1) GG genotype, (2) GT genotype; (E) ApoA5 c.457G>A: (1) GG genotype, (2) GA genotype,
(3) AA genotype.
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Page 6 of 16Figure 3 The linkage disequilibria (LD) among the five SNPs. (A) ApoA1 -75bp G>A, (B) ApoC3 3238C>G, (C) ApoA5 -1131T>C, (D) ApoA5
c.457G>A, and (E) ApoA5 c.553G>T. ApoA1 -75bp G>A was in LD with ApoC3 3238C>G (LD correlation coefficient r = 0.410, P < 0.001), ApoA5
-1131T>C (r = 0.064, P < 0.04), ApoA5 c.553G>T (r = 0.106, P < 0.001), and ApoA5 c.457G>A (r = 0.096, P < 0.002). ApoC3 3238C>G was in LD
with ApoA5 -1131T>C (r = 0.359, P < 0.001). ApoA5 -1131T>C was in LD with ApoA5 c.553G>T (r = 0.245, P < 0.001) and ApoA5 c.457G>A (r =
0.165, P < 0.001). There was no LD between ApoC3 3238C>G and ApoA5 c.553G>T (r = 0.059, P = 0.059) or ApoA5 c.457G>A (r = 0.044, P =
0.155); and between ApoA5 c.553G>T and ApoA5 c.457G>A (r = 0.048, P = 0.126).
Table 2 The genotypic and allelic frequencies of ApoA1/C3/A5 gene polymorphisms between males and females
SNP Group n Genotype [n (%)] Allele [n (%)]
AA AB BB A B
ApoA1 -75bp G>A Male 492 192(39.0) 242(49.2) 58(11.8) 626(63.6) 358(36.4)
(rs1799837) Female 538 210(39.0) 264(49.1) 64(11.9) 684(63.6) 392(36.4)
c
2 - 0.003 0.001
P - 0.998 0.982
ApoC3 3238C>G Male 492 252(51.2) 192(39.0) 48(9.8) 696(70.7) 288(29.3)
(rs5128) Female 538 216(40.2) 264(49.0) 58(10.8) 696(64.7) 380(35.3)
c
2 - 13.053 8.579
P - 0.002 0.003
ApoA5 -1131T>C Male 492 268(54.4) 178(36.2) 46(9.4) 714(72.6) 270(27.4)
(rs662799) Female 538 266(49.4) 226(42.0) 46(8.6) 758(70.4) 318(29.6)
c
2 - 3.663 1.127
P - 0.160 0.288
ApoA5 c.553G>T Male 492 466(94.7) 26(5.3) 0 958(97.4) 26(2.6)
(rs2075291) Female 538 496(92.2) 42(7.8) 0 1034(96.1) 42(3.9)
c
2 - 2.651 2.561
P - 0.103 0.109
ApoA5 c.457G>A Male 492 424(86.2) 64(13.0) 4(0.8) 912(92.7) 72(7.3)
(rs3135507) Female 538 484(90.0) 48(8.9) 6(1.1) 1016(94.4) 60(5.6)
c
2 - 4.605 2.597
P - 0.100 0.107
Allele A: -75bp G, 3238C, -1131T, c.553G or c.457G; Allele B: -75bp A, 3238G, -1131C, c.553T or c.457A; Genotype AA: -75bp GG, 3238CC, -1131TT, c.553GG or
c.457GG; Genotype AB: -75bp GA, 3238CG, -1131TC, c.553GT or c.457GA; Genotype BB: -75bp AA, 3238GG, -1131CC, c.553TT or c.457AA
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As shown in Table 3, the levels of TG in males were dif-
ferent among the GG, GA and AA genotypes of the
ApoA1 -75bp G>A (P < 0.003), whereas the levels of
HDL-C and the ratio of ApoA1 to ApoB in females
were different among the three genotypes (P <0 . 0 5a n d
P < 0.01; respectively).
The levels of HDL-C in males were different among
the CC, CG and GG genotypes of the ApoC3 3238C>G
(P < 0.05), whereas the levels of TG in females were dif-
ferent among the three genotypes (P < 0.01).
The levels of TC, TG, LDL-C, ApoB, and the ratio of
ApoA1 to ApoB in males were different among the TT,
TC and CC genotypes of the ApoA5 -1131T>C (P <
0.05-0.001), whereas the levels of TG in females were
different among the three genotypes (P < 0.001).
The levels of TG and HDL-C in males were different
between the GG and GT genotypes of the ApoA5
c.553G>T (P < 0.01 for each), whereas the levels of
HDL-C in females were different between the two geno-
types (P < 0.05).
The levels of HDL-C and ApoA1 in males were differ-
ent between the GG and GA/AA genotypes of the
ApoA5 c.457G>A (P < 0.001 for each), whereas the
levels of TC, LDL-C, ApoB, and the ratio of ApoA1 to
ApoB in females were different between the GG and
GA/AA genotypes (P < 0.05-0.01).
Haplotypes and serum lipid levels
To examine the combined effect of five variants (in the
order of ApoA5 c.553G>T, ApoA5 c.457G>A, ApoA5
-1131T>C, ApoC3 3238C>G, ApoA1 -75bp G>A) in the
cluster, we conducted haplotype analysis with these
SNPs on the serum lipid traits (Table 4). There were 11
haplotypes with a frequency>1% identified in the cluster
in our population. To increase the statistical power of
analysis, we combined five haplotypes with frequencies
less than 4% into one group, called “rare-hap”,w h i c h
gives a pooled frequency of 9%. The frequencies of
other six haplotypes are listed in Table 4 with G-G-T-
C-G and G-G-T-C-A each accounting for 26% haplo-
type of the population; respectively. At the global level,
the haplotypes comprised of all five SNPs were signifi-
cantly associated with all seven lipid traits (Table 4)
with P values ranging from 1.56 × 10
-6 to 0.001 before
or 0.001 to 0.003 after correcting for multiple testing by
permuation test. In particular, haplotype G-G-C-C-A
(6%) and G-A-T-C-G (4%) showed consistent associa-
tion with TC, LDL-C, ApoA1, ApoB, and the ratio of
ApoA1 to ApoB. In addition, carriers of haplotype G-G-
T-C-G (26%) had increased serum concentration of
HDL-C and ApoA1, whereas carriers of G-G-C-G-G
(15%) had high concentrations of TC, TG, and ApoB.
We also found that haplotypes with five SNPs explain
much more serum lipid variation than any single SNP
alone, especially for TG (4.4% for haplotype vs 2.4% for
-1131T>C max based on R-square) and HDL-C (5.1%
for haplotype vs 0.9% for c.553G>T based on R-square).
Correlation between genotypes and several environment
factors and serum lipid levels
For males, multivariate logistic regression analysis
showed that the levels of TC were correlated with
ApoA5 -1131T>C genotypes; the levels of TG were cor-
related with ApoA1 -75bp G>A and ApoA5 c.553G>T
genotypes, and ApoA5 c.457 G>A, ApoA5 -1131T>C
and ApoC3 3238C>G alleles; the levels of LDL-C were
correlated with ApoC3 3238C>G genotypes; the levels
of ApoB were correlated with ApoA5 c.457 G>A and
ApoC3 3238C>G genotypes; the ratio of ApoA1 to
ApoB was correlated with ApoA1 -75bp G>A and
ApoC3 3238C>G alleles (Table 5).
For females, the levels of TC were correlated with
ApoA5 -1131T>C alleles; the levels of TG were corre-
lated with ApoC3 3238C>G genotypes, the levels of
ApoB were correlated with ApoA1 -75bp G>A and
ApoA5 -1131T>C genotypes, ApoA1 -75bp G>A, ApoC3
3238C>G and ApoA5 c.457 G>A alleles; the ratio of
ApoA1 to ApoB was correlated with ApoA1 -75bp G>A
and ApoA5 -1131T>C genotypes, and ApoA1 -75bp
G>A and ApoC3 3238C>G alleles (Table 5).
Serum lipid parameters were also correlated with sev-
eral environment factors such as age, alcohol consump-
tion, cigarette smoking, blood pressure, body weight,
and BMI (Table 6).
Discussion
The results of the present study clearly show that the
levels of serum HDL-C and ApoA1 in the general Chi-
nese population were higher in females than in males.
There was no significant difference in the levels of TC,
T G ,L D L - C ,A p o Ba n dt h er a t i oo fA p o A 1t oA p o B
between the two sexes. These findings are in good
agreement with those of previous epidemiological stu-
dies [42,43]. Although the effects of gonadal hormones
on blood lipids are considered contributing factors, the
reasons for sex differences in serum lipid levels are still
n o tf u l l yu n d e r s t o o d .I ti sc o m m o n l ya c c e p t e dt h a t
androgens induce changes in lipid concentrations that
would predispose towards CAD, whereas estrogens are
held to have opposite effects [44,45]. However, much of
the evidence for this comes from studies of changes
associated with administration of synthetic gonadal ster-
oids or with changes in gonadal function. Studies of dif-
ferences in lipid metabolism in normal men and women
are extremely limited.
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SNP Genotype n TC
(mmol/L)
TG
(mmol/L)
HDL-C
(mmol/L)
LDL-C
(mmol/L)
ApoA1
(g/L)
ApoB
(g/L)
ApoA1/
ApoB
ApoA1 -75bp G>A Male
(rs1799837) GG 192 4.57 ± 1.06 0.92(0.46) 2.02 ± 0.46 2.40 ± 0.72 1.42 ± 0.18 0.90 ± 0.22 1.67 ± 0.44
GA 242 4.67 ± 1.03 1.05(0.70) 2.06 ± 0.54 2.32 ± 0.79 1.45 ± 0.16 0.89 ± 0.23 1.73 ± 0.52
AA 58 4.51 ± 0.66 0.78(0.54) 1.94 ± 0.37 2.43 ± 0.53 1.41 ± 0.14 0.89 ± 0.21 1.77 ± 1.04
F - 0.867 11.673 1.458 0.894 2.408 0.117 0.914
P - 0.421 0.003 0.234 0.410 0.091 0.890 0.402
Female
GG 210 4.73 ± 0.86 0.99(0.62) 2.15 ± 0.51 2.39 ± 0.65 1.46 ± 0.13 0.90 ± 0.21 1.74 ± 0.56
GA 264 4.68 ± 0.92 0.96(0.59) 2.06 ± 0.42 2.48 ± 0.66 1.45 ± 0.14 0.93 ± 0.20 1.61 ± 0.35
AA 64 4.61 ± 0.94 0.96(0.59) 2.01 ± 0.47 2.43 ± 0.69 1.42 ± 0.13 0.93 ± 0.21 1.60 ± 0.34
F - 0.477 0.236 3.273 1.094 2.153 1.369 5.689
P - 0.621 0.889 0.039 0.336 0.117 0.255 0.004
ApoC3 3238C>G Male
(rs5128) CC 252 4.57 ± 0.96 0.93(0.65) 1.97 ± 0.45 2.34 ± 0.76 1.42 ± 0.15 0.88 ± 0.23 1.75 ± 0.69
CG 192 4.61 ± 1.02 1.00(0.50) 2.11 ± 0.57
b 2.35 ± 0.66 1.44 ± 0.19 0.89 ± 0.20 1.68 ± 0.42
GG 48 4.85 ± 1.21 1.02(0.60) 2.07 ± 0.36 2.57 ± 0.90 1.45 ± 0.15 0.96 ± 0.27 1.64 ± 0.46
F - 1.551 2.954 4.528 2.036 1.138 2.601 1.213
P - 0.213 0.228 0.011 0.132 0.321 0.075 0.298
Female
CC 216 4.65 ± 0.80 0.92(0.60) 2.08 ± 0.42 2.45 ± 0.62 1.45 ± 0.12 0.91 ± 0.17 1.64 ± 0.31
CG 264 4.67 ± 0.98 0.98(0.64) 2.10 ± 0.48 2.41 ± 0.68 1.44 ± 0.14 0.92 ± 0.21 1.67 ± 0.46
GG 58 4.93 ± 0.87 1.02(1.00) 2.05 ± 0.53 2.56 ± 0.72 1.45 ± 0.12 0.95 ± 0.25 1.68 ± 0.73
F - 2.342 15.113 0.314 1.249 0.403 0.920 0.339
P - 0.097 0.001 0.731 0.288 0.668 0.399 0.712
ApoA5 -1131T>C Male
(rs662799) TT 268 4.56 ± 1.01 0.91(0.53) 2.04 ± 0.48 2.33 ± 0.76 1.43 ± 0.15 0.88 ± 0.22 1.76 ± 0.68
TC 178 4.58 ± 1.01 1.03(0.66) 1.99 ± 0.49 2.34 ± 0.70 1.42 ± 0.19 0.90 ± 0.22 1.67 ± 0.42
CC 46 5.08 ± 0.90 1.14(0.72) 2.15 ± 0.56 2.66 ± 0.67 1.47 ± 0.12 0.99 ± 0.22 1.57 ± 0.42
F - 7.637 13.443 0.535 4.492 0.135 8.091 7.797
P - 0.001 0.001 0.586 0.012 0.873 0.000 0.000
Female
TT 266 4.60 ± 0.84 0.89(0.58) 2.09 ± 0.42 2.39 ± 0.66 1.44 ± 0.13 0.90 ± 0.19 1.69 ± 0.38
TC 226 4.77 ± 0.99 1.04(0.64) 2.10 ± 0.52 2.49 ± 0.67 1.45 ± 0.14 0.95 ± 0.20 1.61 ± 0.41
CC 46 4.79 ± 0.77 1.01(1.04) 2.03 ± 0.45 2.48 ± 0.64 1.45 ± 0.12 0.93 ± 0.25 1.74 ± 0.78
F - 1.662 16.015 0.272 1.233 0.333 2.154 0.278
P - 0.191 0.000 0.762 0.292 0.717 0.117 0.758
ApoA5 c.553G>T Male
(rs2075291) GG 466 4.61 ± 1.02 0.93(0.56) 2.05 ± 0.50 2.36 ± 0.74 1.43 ± 0.16 0.89 ± 0.22 1.72 ± 0.58
GT 26 4.64 ± 0.87 1.63(1.39) 1.74 ± 0.33 2.38 ± 0.75 1.39 ± 0.18 0.96 ± 0.27 1.62 ± 0.67
F - 0.147 4.108 3.122 0.134 1.232 1.559 0.848
P - 0.883 0.000 0.002 0.893 0.218 0.120 0.397
Female
GG 496 4.70 ± 0.91 0.98(0.60) 2.10 ± 0.47 2.44 ± 0.66 1.45 ± 0.14 0.92 ± 0.20 1.66 ± 0.45
GT 42 4.60 ± 0.82 0.97(0.74) 1.97 ± 0.33 2.39 ± 0.61 1.45 ± 0.09 0.95 ± 0.21 1.60 ± 0.35
F - 0.689 0.844 2.359 0.474 0.000 0.930 0.843
P - 0.491 0.399 0.018 0.636 1.000 0.353 0.399
ApoA5 c.457G>A Male
(rs3135507) GG 424 4.63 ± 0.96 1.00(0.58) 2.07 ± 0.49 2.38 ± 0.74 1.44 ± 0.15 0.90 ± 0.22 1.72 ± 0.59
GA/AA 68 4.51 ± 1.26 1.01(0.63) 1.79 ± 0.43 2.30 ± 0.73 1.36 ± 0.22 0.88 ± 0.22 1.64 ± 0.50
F - 0.913 -0.268 4.445 0.829 3.795 0.696 1.059
P - 0.362 0.788 0.000 0.407 0.000 0.487 0.290
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Female
GG 484 4.72 ± 0.91 0.98(0.59) 2.09 ± 0.47 2.47 ± 0.66 1.45 ± 0.14 0.93 ± 0.20 1.64 ± 0.43
GA/AA 54 4.40 ± 0.81 0.94(0.45) 2.06 ± 0.38 2.21 ± 0.65 1.43 ± 0.10 0.84 ± 0.20 1.82 ± 0.52
F - 2.477 0.589 0.453 2.750 1.021 3.137 2.452
P - 0.014 0.556 0.651 0.006 0.309 0.002 0.014
SNP, single nucleotide polymorphism; TC, total cholesterol; TG, triglyceride; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol;
ApoA1, apolipoprotein A1; ApoB, apolipoprotein B; ApoA1/ApoB, the ratio of apolipoprotein A1 to apolipoprotein B. The values of TG were presented as median
(interquartile range). The difference among the genotypes was determined by the Kruskal-Wallis test or the Wilcoxon-Mann-Whitney test.
Table 4 Association between ApoA1/C3/A5 haplotypes and serum lipid levels in the combined population of males
and females
Lipid Haplotype G-G-T-C-
G
G-G-T-C-
A
G-G-C-G-
G
G-G-T-G-
G
G-G-C-C-
A
G-A-T-C-
G
Rare Hap Haplotype global association
- Frequency 0.26 0.26 0.15 0.13 0.06 0.04 0.09 - -
- Frequency (carrier
vs
Noncarrier)
462 vs.
568
458 vs.
572
328 vs.
702
236 vs.
794
118 vs.
912
92 vs. 938 62 vs. 968 PP after
permutation
correction
TC Carrier 4.67 ±
0.05
4.64 ±
0.05
4.78 ±
0.06
4.71 ±
0.07
4.87 ±
0.09
4.40 ±
0.10
4.70 ±
0.08
(mmol/
L)
Noncarrier 4.70 ±
0.05
4.72 ±
0.05
4.64 ±
0.05
4.68 ±
0.04
4.66 ±
0.04
4.71 ±
0.04
4.69 ±
0.04
P 0.514 0.159 0.024 0.641 0.021 0.002 0.882 2.05E-
04
0.001
TG Carrier 1.10 (0.07) 1.23 (0.07) 1.38 (0.08) 1.20 (0.09) 1.27 (0.12) 1.73 (0.13) 1.15 (0.16)
(mmol/
L)
Noncarrier 1.33 (0.07) 1.23 (0.07) 1.16 (0.06) 1.24 (0.06) 1.23 (0.06) 1.19 (0.06) 1.24 (0.06)
P 0.004 0.121 < 0.001 0.866 0.324 0.426 0.055 1.50E-
05
0.001
HDL-C Carrier 2.15 ±
0.03
2.11 ±
0.03
2.14 ±
0.03
2.14 ±
0.04
2.12 ±
0.05
1.95 ±
0.05
2.02 ±
0.04
(mmol/
L)
Noncarrier 2.09 ±
0.03
2.12 ±
0.03
2.10 ±
0.02
2.11 ±
0.02
2.11 ±
0.02
2.13 ±
0.02
2.13 ±
0.02
P 0.049 0.835 0.279 0.350 0.933 < 0.001 0.014 1.56E-
06
0.001
LDL-C Carrier 2.38 ±
0.04
2.37 ±
0.04
2.45 ±
0.04
2.40 ±
0.05
2.52 ±
0.06
2.14 ±
0.07
2.43 ±
0.06
(mmol/
L)
Noncarrier 2.41 ±
0.04
2.42 ±
0.04
2.37 ±
0.03
2.40 ±
0.03
2.38 ±
0.03
2.42 ±
0.03
2.39 ±
0.03
P 0.405 0.311 0.085 0.978 0.033 < 0.001 0.561 0.001 0.003
ApoA1 Carrier 1.48 ±
0.01
1.46 ±
0.01
1.46 ±
0.01
1.47 ±
0.01
1.49 ±
0.01
1.41 ±
0.02
1.45 ±
0.01
(g/L) Noncarrier 1.46 ±
0.01
1.47 ±
0.01
1.47 ±
0.01
1.46 ±
0.01
1.46 ±
0.01
1.47 ±
0.01
1.47 ±
0.01
P 0.025 0.581 0.832 0.272 0.043 < 0.001 0.327 6.97E-
05
0.001
ApoB Carrier 0.90 ±
0.01
0.90 ±
0.01
0.93 ±
0.01
0.91 ±
0.02
0.96 ±
0.02
0.83 ±
0.02
0.94 ±
0.02
(g/L) Noncarrier 0.92 ±
0.01
0.92 ±
0.01
0.90 ±
0.01
0.91 ±
0.01
0.91 ±
0.01
0.92 ±
0.01
0.91 ±
0.01
P 0.171 0.207 0.029 0.797 0.008 < 0.001 0.062 6.85E-
06
0.001
ApoA1/ Carrier 1.72 ±
0.03
1.72 ±
0.03
1.67 ±
0.03
1.70 ±
0.04
1.59 ±
0.05
1.81 ±
0.06
1.65 ±
0.05
ApoB Noncarrier 1.69 ±
0.03
1.69 ±
0.03
1.72 ±
0.03
1.70 ±
0.02
1.72 ±
0.02
1.69 ±
0.02
1.71 ±
0.02
P 0.357 0.211 0.115 0.975 0.011 0.031 0.173 0.001 0.003
TC, total cholesterol; TG, triglyceride; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; ApoA1, apolipoprotein A1; ApoB,
apolipoprotein B; ApoA1/ApoB, the ratio of apolipoprotein A1 to apolipoprotein B
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quencies in this gene cluster, but the present study
shows that there was no significant difference in the
allelic and genotypic frequencies of the all SNPs except
ApoC3 3238C>G between males and females. The fre-
quency of ApoC3 3238G allele was lower in males than
in females (29.3% vs. 35.3%, P < 0.01). The frequency of
CG and GG genotypes was also lower in males than in
females (P < 0.01). The frequency of ApoA1 -75bp A
allele was higher in our population than in Liangshan Yi
(23.0%), the other minority in China [46], and Cauca-
sians (12.4-21.8%) in the western countries [47,48]. Rare
allelic frequency of Caucasians from different nations
was similar and significantly lower than that of oriental
races. The frequency of ApoC3 3238G allele in our
population was consistent with ranges reported for Chi-
nese (30-43%) [29,49], Japanese (25-48%) [50] and
Indians (36%) [51], but are higher than that reported for
Caucasians in whom the G allele frequency was 0-11%
[51,52]. The ApoA5 -1131C allele in our study popula-
tion was similar to that in Chinese (29.9%) [53,54], Sin-
gaporean Chinese (29.4%) [55], Malays (30.0%) [55],
slightly lower than that in Japanese (34.0%) [56,57], but
much greater than that of whites (8.0%) [12], Hispanic
Americans (16.0%) [16,58,59] or Tunisian (13.0%) [60].
The frequency of ApoA5 c.553T allele in this study is
extremely low, and is in agreement with that of two pre-
vious studies in Chinese (3.97%) [61] and Chinese
Table 5 Correlation between serum lipid parameters and alleles/genotypes in the males and females
Lipid parameter Risk factor c
2 P Odds ratio 95% CI
Male plus female
TC ApoA5 -1131T>C allele 12.284 0.000 1.704 1.265-2.295
TG ApoA5 c.553G>T genotype 5.986 0.014 2.293 1.180-4.460
ApoA5 c.457 G>A allele 7.713 0.005 2.243 1.268-3.968
ApoA5 -1131T>C allele 6.647 0.010 1.534 1.108-2.123
ApoA1 -75bp G>A genotype 5.337 0.021 0.345 0.140-0.851
HDL-C ApoA5 c.457 G>A allele 7.595 0.006 16.571 2.250-12.048
LDL-C ApoC3 3238C>G genotype 12.001 0.001 2.834 1.572-5.111
ApoA1 ApoA5 c.553G>T genotype 4.978 0.026 11.297 1.343-5.052
ApoB ApoC3 3238C>G genotype 13.034 0.000 1.514 1.209-1.897
Male
TC ApoA5 -1131T>C genotype 4.910 0.027 1.428 1.042-1.957
TG ApoA5 c.553G>T genotype 17.322 0.000 7.990 3.003-21.260
ApoA5 c.457 G>A allele 4.097 0.043 2.263 1.026-4.989
ApoA5 -1131T>C allele 7.400 0.007 2.590 1.305-5.143
ApoC3 3238C>G allele 3.904 0.048 0.503 0.254-0.995
ApoA1 -75bp G>A genotype 5.372 0.020 0.240 0.072-0.802
LDL-C ApoC3 3238C>G genotype 8.307 0.004 1.886 1.225-2.904
ApoB ApoA5 c.457 G>A genotype 4.600 0.032 0.464 0.230-0.936
ApoC3 3238C>G genotype 4.284 0.038 2.088 1.040-4.193
ApoA1/ApoB ApoC3 3238C>G allele 6.836 0.009 0.354 0.163-0.771
ApoA1 -75bp G>A allele 3.939 0.047 6.065 1.023-35.968
Female
TC ApoA5 -1131T>C allele 19.701 0.000 2.651 1.724-4.078
TG ApoC3 3238C>G genotype 26.171 0.000 3.149 2.029-4.887
ApoB ApoA5 c.457 G>A allele 7.720 0.005 2.961 1.377-6.368
ApoA5 -1131T>C genotype 5.390 0.020 1.600 1.076-2.379
ApoC3 3238C>G allele 14.382 0.000 3.403 1.807-6.407
ApoA1 -75bp G>A genotype 6.842 0.009 3.043 1.322-7.007
ApoA1 -75bp G>A allele 4.409 0.036 0.318 0.109-0.927
ApoA1/ApoB ApoA5 -1131T>C genotype 7.771 0.005 6.339 1.730-23.221
ApoC3 3238C>G allele 5.542 0.019 13.522 1.546-118.228
ApoA1 -75bp G>A genotype 5.519 0.019 14.950 1.566-142.771
ApoA1 -75bp G>A allele 7.989 0.005 0.017 0.001-0.287
TC, total cholesterol; TG, triglyceride; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; ApoA1, apolipoprotein A1; ApoB,
apolipoprotein B; ApoA1/ApoB, the ratio of apolipoprotein A1 to apolipoprotein B
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Lipid parameter Risk factor c
2 P Odds ratio 95% CI
Male plus female
TC Age 53.062 0.000 1.034 1.025-1.043
Height 8.532 0.003 0.847 0.757-0.947
Weight 10.525 0.001 1.329 1.119-1.578
Body mass index 6.797 0.009 0.593 0.401-0.878
Cigarette smoking 6.455 0.011 0.748 0.598-0.936
TG Age 6.792 0.009 1.017 1.004-1.029
Height 16.601 0.000 0.777 0.688-0.877
Weight 16.820 0.000 1.476 1.225-1.778
Body mass index 9.241 0.002 0.522 0.343-0.794
Alcohol consumption 10.147 0.001 1.606 1.200-2.149
LDL-C Ethnic group 10.381 0.001 0.492 0.320-0.758
Sex 5.359 0.021 1.728 1.088-2.747
Age 28.500 0.000 1.038 1.024-1.052
Weight 44.497 0.000 1.099 1.069-1.129
Alcohol consumption 4.813 0.028 0.702 0.511-0.963
ApoA1 Height 13.117 0.000 1.451 1.186-1.775
Weight 9.403 0.002 0.719 0.583-0.888
Diastolic blood pressure 7.697 0.006 0.892 0.822-0.967
Cigarette smoking 6.813 0.009 7.213 1.636-13.806
ApoB Sex 4.652 0.031 0.665 0.459-0.963
Height 4.215 0.040 0.903 0.819-0.995
Weight 5.765 0.016 1.213 1.036-1.419
Body mass index 4.364 0.037 0.678 0.471-0.976
Alcohol consumption 5.787 0.016 0.744 0.585-0.947
ApoA1/ApoB Ethnic group 3.987 0.046 1.752 1.010-3.037
Height 9.623 0.002 0.815 0.716-0.927
Weight 12.059 0.001 1.451 1.176-1.791
Body mass index 14.889 0.000 0.374 0.227-0.616
Male
TC Age 5.116 0.024 1.016 1.002-1.031
Height 5.474 0.019 0.956 0.921-0.993
Weight 26.172 0.000 1.113 1.068-1.160
TG Weight 20.023 0.000 1.152 1.083-1.226
Diastolic blood pressure 4.879 0.027 0.967 0.938-0.996
Alcohol consumption 14.437 0.000 2.291 1.494-3.513
LDL-C Ethnic group 5.224 0.022 0.449 0.226-0.892
Age 8.301 0.004 1.035 1.011-1.060
Height 14.963 0.000 1.096 1.046-1.148
Body mass index 22.094 0.000 1.418 1.226-1.640
ApoA1 Height 6.700 0.010 18.279 2.025-5.008
Weight 6.201 0.013 0.022 0.001-0.442
ApoB Height 4.635 0.031 0.866 0.760-0.987
Weight 5.439 0.020 1.285 1.041-1.587
Body mass index 4.398 0.036 0.576 0.345-0.965
Systolic blood pressure 9.347 0.002 1.026 1.009-1.044
Alcohol consumption 4.211 0.040 0.736 0.549-0.986
ApoA1/ApoB Ethnic group 4.973 0.026 2.286 1.105-4.731
Female
TC Age 46.796 0.000 1.051 1.036-1.066
Weight 6.720 0.010 1.040 1.010-1.071
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Page 12 of 16Taiwanese (4.2-7.2%) [62,63]. The ApoA5 c.553T allele
has been reported to be absent in Caucasians [64]. The
ApoA5 c.553TT homozygous was not detected in our
study population. This is similar to the results in a pre-
vious study [61]. The frequency of ApoA5 c.457A allele
was lower in our study population than in Chinese Tai-
wanese (10.27%) [54], but was higher than that reported
for Czechoslovakians in whom the ApoA5 c.457A allele
frequency was 2.04% [65]. These results suggest that
there exists significant racial/ethinc variation of allelic
frequencies in the ApoA1/C3/A5 gene cluster.
The association of the ApoA1/C3/A5 gene poly-
morphisms and plasma or serum lipid levels in humans
has been evaluated in a large number of studies [13-30].
However, previous findings are inconsistent [31-38].
Talmud et al. [66] found that the ApoA1 -75 bp A allele
induced elevated HDL-C and ApoA1 levels. This rela-
tionship was also demonstrated in many other studies,
but with sex-dependent: Jeenah et al. [67] and Sigurds-
son et al. [68] found in British and Icelandic male
respectively that A allele confered high serum ApoA1
levels. Xu et al. [69] reported A allele carriers had higher
mean levels of TC, LDL-C, ApoB and ApoA1 than G
homozygotes in Italian boys. Nevertheless, Pagani et al.
[70] discovered A allele was positively related to HDL-C
concentration in Italian female exclusively. There were
also some studies detecting no correlation between the
ApoA1 -75 bp G>A and serum lipids pattern [31,32].
Previous cohort studies, as well as case-control and
familial studies have shown significant association
between the ApoC3 3238G allele and higher plasma TG
levels [13-30]. However, several reports failed to find a
significant genetic effect on TG concentrations [33-35].
In a previous work, Kee and coworkers found no asso-
ciation between ApoC3 3238C>G polymorphism and
lipids, lipoproteins and complex lipoprotein particles in
as a m p l eo fm e nf r o mn o r t h e r nF r a n c e[ 3 4 ] .T h e y
thought that the ApoC3 3238C>G polymorphism is not
major contributors to the risk of dyslipidemia in the
population of northern France. Several separate clinical
studies have provided consistent and strong support for
the effect with 24% of whites, 35% of blacks, and 53% of
Hispanics who carry ApoA5 -1131C allele associated
with increased plasma TG levels [12,16,58]. But this
association was not significant in a population-based
Spanish control group [38]. The ApoA5 c.553G>T poly-
morphism has been found to correlate strongly with TG
levels in Chinese but not in Caucasians [62,64]. The
ApoA5 c.553T allele carriers had significantly higher
plasma TG levels compared to the wide-type GG
Table 6 Correlation between serum lipid parameters and several environmental factors in the males and females
(Continued)
TG Age 8.060 0.005 1.028 1.009-1.048
Height 14.564 0.000 0.648 0.519-0.810
Weight 13.307 0.000 1.956 1.364-2.805
Body mass index 9.570 0.002 0.288 0.131-0.643
Systolic blood pressure 5.469 0.019 1.024 1.004-1.045
HDL-C Systolic blood pressure 3.389 0.048 0.870 0.758-0.999
LDL-C Ethnic group 5.274 0.022 0.506 0.283-0.905
Age 14.902 0.000 1.038 1.018-1.058
Height 5.072 0.024 1.061 1.008-1.116
Body mass index 11.305 0.001 1.175 1.070-1.291
ApoA1 Weight 4.470 0.034 0.258 0.074-0.906
Systolic blood pressure 6.152 0.013 0.583 0.380-0.893
Pulse pressure 5.363 0.021 1.526 1.067-2.183
ApoB Age 14.358 0.000 1.032 1.015-1.049
Weight 5.156 0.023 1.460 1.053-2.023
Body mass index 4.428 0.035 0.462 0.225-0.948
Pulse pressure 4.620 0.032 0.975 0.952-0.998
Cigarette smoking 4.129 0.042 0.303 0.096-0.959
ApoA1/ApoB Age 6.236 0.013 1.037 1.008-1.067
Height 9.500 0.002 0.547 0.373-0.803
Weight 9.508 0.002 2.833 1.461-5.492
Body mass index 11.423 0.001 0.080 0.019-0.346
Pulse pressure 5.817 0.016 0.942 0.897-0.989
TC, total cholesterol; TG, triglyceride; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; ApoA1, apolipoprotein A1; ApoB,
apolipoprotein B; ApoA1/ApoB, the ratio of apolipoprotein A1 to apolipoprotein B
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Page 13 of 16genotype, in both CAD and control groups. In a pre-
vious study, however, Tang et al. [61] did not find any
significant associations between the ApoA5 c.553G>T
polymorphism and plasma lipid parameters such as TC,
LDL-C, HDL-C, ApoA1, and ApoB in Han Chinese
recruited from Jiangsu Province, People’s Republic of
China. The association of the ApoA5 c.457G>A poly-
morphism and plasma lipid levels in humans has not
been fully elucidated. In a previous study, Kao et al. [62]
showed that the ApoA5 c.457G>A polymorphism was
not associated with serum TG levels in normal people.
In another recent study, Hubacek et al. [65] showed that
the impact of statin treatment on lipid parameters did
not significantly differ between carriers of the genotypes
defined by the ApoA5 c.457G>A polymorphisms. In the
present study, we showed that the ApoA5 c.457A allele
carriers in males had lower serum HDL-C and ApoA1
levels than the A allele noncarriers, whereas the ApoA5
c.457A allele carriers in females had lower serum TC,
LDL-C and ApoB levels and higher the ratio of ApoA1
to ApoB than the A allele noncarriers.
Important intra- and inter-genic LD associations have
been found in this study, which replicate previous find-
ings [26-30]. These LD patterns in ApoA1/C3/A5 are
rather complex and highly specific to the population
under study and indicate the functional dependencies of
the encoded proteins [24]. In the present study, haplo-
type analysis with all five SNPs further supports the
strong association between ApoA1/C3/A5 gene poly-
morphisms and serum lipid levels in our study popula-
tion. At the global level, the haplotypes comprised of all
five SNPs were significantly associated with all seven
lipid traits after correcting for multiple testing by per-
muation test. In particular, haplotype G-G-C-C-A and G-
A-T-C-G showed consistent association with LDL-C, TC,
ApoA1, ApoB, and the ratio of ApoA1 to ApoB. In addi-
tion, carriers of haplotype G-G-T-C-G had increased
serum concentration of HDL-C and ApoA1, whereas car-
riers of G-G-C-G-G had high concentrations of TG, TC,
and ApoB. We also found that haplotypes with five SNPs
explain much more serum lipid variation than any single
SNP alone, especially for TG and HDL-C.
The present study has some shortcomings. Firstly, the
size of our study population is a bit small, which might
not have had the power to detect the LD across the
ApoA1/C3/A5 locus. The individual with ApoA5 c.553TT
genotype is not detected in our population, and the num-
ber of subjects with ApoA5 c.457AA genotype in both
sexes is also small. It has been postulated that an adequate
analysis of the polymorphic variants of the ApoA1/
ApoC3/ApoA4 gene complex requires a sample of at least
600 subjects to allow the detection of a twofold increased
risk of disease [71]. Secondly, the levels of body height,
weight, systolic blood pressure, diastolic blood pressure,
pulse pressure, the prevalence of hypertension, and the
percentages of subjects who consumed alcohol or smoked
cigarettes were higher in males than in femailes. Although
age, BMI, blood pressure, alcohol consumption, and cigar-
ette smoking have been adjusted for the statistical analysis,
we can not completely exclude the influence of these fac-
tors on serum lipid levels among different genotypes in
both sexes. Thirdly, because we selected the SNPs from lit-
erature and did not cover the extensive ApoA1/C3/A4/A5
gene locus, we might miss some information from other
SNPs. We did not include ApoA4 SNPs in this study,
because there is no ApoA4 SNP is associated with hyper-
triglyceridemia [29], except ApoA4 T347S associated with
a TG-lowering effect [16]. Chien et al. [30] have analyzed
amino acid 360 (G to T substitution, Glu to His) and
amino acid 347 (A to T, Thr to Ser) of the ApoA4 gene
but the results showed no substitution was found in a
community-based population.
Conclusion
T h ep r e s e n ts t u d ys h o w st h a tt h ea l l e l i ca n dg e n o t y p i c
frequencies of the all SNPs except ApoC3 3238C>G
were not different between males and females, but all
five SNPs at the ApoA1/C3/A5 gene cluster and their
haplotypes are closely associated with modifications of
serum lipid parameters in both sexes. The haplotypes
with five SNPs explain much more serum lipid variation
than any single SNP alone, especially for TG and HDL-
C in the general Chinese population.
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